GUANGZHOU, China, April  28, 2026  (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the &#34;Company&#34; or &#34;Burning Rock&#34;)), a company focused on the application of next generation sequencing technology in the

Burning Rock Publishes 2025 Annual Report on Form 20-F

Burning Rock Biotech Files Annual Report with SEC, Highlights Progress

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>GUANGZHOU, China, April  28, 2026  (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the &amp;#34;Company&amp;#34; or &amp;#34;Burning Rock&amp;#34;)), a company focused on the application of next generation sequencing technology in the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Burning Rock Biotech has filed its Annual Report for 2025, showcasing advancements in next generation sequencing technology for oncology. With a focus on precision medicine and clinical validation of early detection tests, BNR continues to drive innovation in cancer diagnostics, which could lead to increased investor interest and potential stock appreciation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>BNR filed its Annual Report on Form 20-F for 2025 on April 28, 2026.</li><li>The report includes audited consolidated financial statements for shareholders.</li><li>BNR focuses on next generation sequencing technology in precision oncology.</li><li>Cancer early detection testing has moved to clinical validation stage.</li><li>Company will provide hard copies of the report upon request.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Burning Rock Biotech Limited (BNR)</strong>: Focusing on oncology solutions indicates potential for market growth and investment.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This press release falls under &#039;Corporate Developments&#039; as it highlights BNR&#039;s operational progress and its future direction in oncology. As the company expands its clinical offerings, it may bolster its competitive edge in a lucrative market segment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The progress in early detection clinical validation may significantly enhance BNR&#039;s market position.</li><li>Filing the substantial report may restore investor confidence and interest in BNR.</li><li>Any future partnerships or further advancements become critical for capitalizing on BNR&#039;s growth potential.</li><li>Improved financial metrics highlighted in the report can attract institutional investment.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>BNR filed its Form 20-F on April 28, 2026.</li><li>The report contains audited financial statements for 2025.</li><li>BNR specializes in next generation sequencing technology.</li><li>The company is advancing cancer early detection to clinical validation.</li><li>Hard copies of the report are available upon request for stakeholders.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying BNR as its clinical advancements may attract positive market attention in Q2 2026.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>GUANGZHOU, China, April  28, 2026  (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BNR">BNR</a>, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 28, 2026 it filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F") with the U.S. Securities and Exchange Commission ("SEC"). The Form 20-F is available for viewing on the SEC website at <a href="https://www.globenewswire.com/Tracker?data=GqP_NI5hiXbzL62dLhM5IniG3HwsGxR6ynBcKVsIeu_Cd1QVa63u4JNbGb8wIJ9DMgmZGanAJ3s5oY6Qp5-mlpufcbG1tvXZyrIh6-9De-qSlL3NMbBEAmPe2eGLkBgj-rkxP74XjNRX1iArds9EhLAxnglzcgme6w6qTHkQaX7ucVBsqzPiRqvzP35UN2n5UcLDK17GsUyldSysz118WaFQPVyYiqC-09F7vg1OU7o=" rel="nofollow" target="_blank"><u>www.sec.gov</u></a> and also on the Company's website at <a href="https://www.globenewswire.com/Tracker?data=ACt2enLwZztoRSYA4xf9GR86aBPZ-dg_J7RSwCkc1Ji6CRnD_v3CrFZryAHPR04NDzxLH-0ljnLQ78cEao1pjtAsHaMSOSa_ym2Wr39dxdE=" rel="nofollow" target="_blank">http://ir.brbiotech.com.</a> The Company will provide a hard copy of the Form 20-F containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Burning Rock Biotech Limited, No.5 Xingdao Ring Road North, International Bio Island, Guangzhou, or via email at <a href="mailto:IR@brbiotech.com">IR@brbiotech.com</a>.</p>  <p><strong>About</strong> <strong>Burning</strong> <strong>Rock</strong></p>  <p align="justify">Burning Rock Biotech Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BNR">BNR</a>), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&amp;D into the clinical validation stage.</p>  <p>For more information about Burning Rock, please visit: <a href="https://www.globenewswire.com/Tracker?data=ACt2enLwZztoRSYA4xf9GR86aBPZ-dg_J7RSwCkc1JhIO2efKes37q8YP29_mrNlw5apFKC0kx4M1fCHHxHEHcOgcMweazhwsg8H4fhjQezJnHiP6jSgSse0UKkbJRBxBz4SmB7FEDVohmaSZ256SeUk4CBkub5Ty7KC9i4_E7ucujKfm46qGVtXxiF7qc2MOLmsxp1hDVGYroie4LiMGHiQN42oAzJ8gu3wplw_Bu8bstpixzwds-nhWSQ1spIeZsyIb8x7k_26PTj4lLct5A==" rel="nofollow" target="_blank"><u>http://ir.brbiotech.com</u></a></p>  <p><strong>Safe</strong> <strong>Harbor</strong> <strong>Statement</strong></p>  <p>This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.</p>  <p>Contact: <a href="https://www.globenewswire.com/Tracker?data=t0Smp3LLleeJsZNL74WmBA39NZmuG0T2KFKe3sV7DKU_F4N2H7sScnmK4bOF3DuVMjnvlTVuBm4ybCeeYFKbI1ooc1XG1ZpeMGiiPQof58usj97KUfuOEiMWa7B9iRm-K4JT_w9dlIg5J59w98rjbr6Ddl4Fq-r28vHLNm_JEJrK6z4_daVS9qVT0w68ziQiysaFUmYXz7GVp2YgstU90lpZhTLxQbCpIRJW5m3D8ZJPzZod3xKNj4XkXKyhI8KH" rel="nofollow" target="_blank"><u>IR@brbiotech.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwODM2NSM3NTY5OTEwIzIxOTUyNTk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZmJkMTkyMTItMTNlNS00MmY2LWEwMmEtYThlZDI2MzNkZWFlLTEyMDY4MTItMjAyNi0wNC0yOC1lbg==/tiny/Burning-Rock-Biotech-Limited.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/904d8c1b-eae2-4b6f-83ed-3cb8d0ad31f6"><img src="https://ml.globenewswire.com/media/904d8c1b-eae2-4b6f-83ed-3cb8d0ad31f6/small/logo-01-png.png" border="0" width="150" height="71" alt="Primary Logo"></img></a></p>

Burning Rock Biotech has filed its Annual Report for 2025, showcasing advancements in next generation sequencing technology for oncology. With a focus on precision medicine and clinical validation of early detection tests, BNR continues to drive innovation in cancer diagnostics, which could lead to increased investor interest and potential stock appreciation.

Burning Rock Publishes 2025 Annual Report on Form 20-F

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News